Recombinant Human Annexin A9(ANXA9),partial CSB-EP001852HU
Specifications
| 20ug / 100ug / 1mg price = 100ug |
Alternative Name(s):
Annexin XXXI;Annexin-31;Annexin-9;Pemphaxin
Species: (Organism)
Homo sapiens (Human)
Gene Names:
ANXA9
Tag info:
N-terminal 6xHis-SUMO-tagged
Target Protein AA Sequence:
MAPSLTQEILSHLGLASKTAAWGTLGTLRTFLNFSVDKDAQRLLRAITGQGVDRSAIVDVLTNRSREQRQLISRNFQERTQQDLMKSLQAALSGNLERIVMALLQPTAQFDAQELRTALKASDSAVDVAIEILATRTPPQLQECLAVYKHNFQVEAVDDITSETSGILQDLLLALAKGGRDSYSGIIDYNLAEQDVQALQRAEGPSREETWVPVFTQRNPEHLIRVFDQYQRSTGQELEEAVQNRFHGDAQVALLGLASVIKNTPLYFADKLHQALQETEPNYQVLIRILISRCETDLLSIRAEFRKKFGKSLYSSLQDAVKGDCQSALLALCRAEDM
Expression Region:
8-345aa
Subcellular Location:
Tissue Specificity:
Expressed in the stratified squamous skin epithelium, but not in epithelia of other types (at protein level).
Protein Length:
Partial
Pathway:
Mol. Weight:
53.7 kDa
Purity:
Greater than 90% as determined by SDS-PAGE.
Form:
Liquid or Lyophilized powder
Buffer:
If the delivery form is liquid, the default storage buffer is Tris/PBS-based buffer, 5%-50% glycerol. If the delivery form is lyophilized powder, the buffer before lyophilization is Tris/PBS-based buffer, 6% Trehalose, pH 8.0.
Research Areas:
Signal Transduction
Function:
Low affinity receptor for acetylcholine known to be targeted by disease-causing pemphigus vulgaris antibodies in keratinocytes.
Involvement in disease:
Relevance:
Low affinity receptor for acetylcholine known to be targeted by disease-causing pphigus vulgaris antibodies in keratinocytes.
Reconstitution:
We recommend that this vial be briefly centrifuged prior to opening to bring the contents to the bottom. Please reconstitute protein in deionized sterile water to a concentration of 0.1-1.0 mg/mL.We recommend to add 5-50% of glycerol (final concentration) and aliquot for long-term storage at -20℃/-80℃. Our default final concentration of glycerol is 50%. Customers could use it as reference.
Protein Families:
Annexin family
Reference:
Expression profile and structural divergence of novel human annexin 31.Morgan R.O., Fernandez M.-P.FEBS Lett. 434:300-304(1998)
